Press Releases and Blog
Blog
“Delinking” Legislation Provides Big Pharma With $32 Billion Bailout Annually While Costing Patients And Families Up To $27 Billion In Increased Premiums
The so-called “delinking” policy made news last week with the introduction of H.R. 6283. Among several glaring problems — including a rejection of free market
ICYMI: Competitive Enterprise Institute Explains How Pharmacy Benefit Companies Lower Health Care Costs
In case you missed it, the Competitive Enterprise Institute (CEI) released a new video, “Pharmacy Benefit Managers and Healthcare Costs: Not a Policy Paper, Just
ICYMI: Joe Grogan: Congress Wants A Better Value. So Why Are They Eliminating Performance Based Payment?
In case you missed it, Joe Grogan, visiting senior fellow at the USC Schaeffer Center and former domestic policy adviser under the previous administration, asked
ICYMI: New Survey Finds Overwhelming Majority of Employers Value a Wide Range of Pharmacy Benefit Company Contract Options
Approximately 9 in 10 Employers Find Pharmacy Benefit Companies Valuable When Designing their Pharmacy Benefits and Say Flexibility and Choice are Essential In case you
Employers Choose Spread Pricing for a Reason
Millions of Patients Impacted if Option to Use Spread Pricing is Taken Away Pharmacy benefit companies offer employers and health plans flexibility when they’re designing
Correcting the Record: Pharmacy Benefit Companies Support and Promote Generics and Biosimilars
Pharmacy benefit companies actively promote the use of generics and biosimilars. Take a look at the data on drug utilization: 90 percent of prescriptions dispensed
Press Releases
PCMA Applauds Reintroduction of Bipartisan Solutions to Crack Down on Big Drug Companies’ Patent Abuse
Blumenthal-Cornyn Legislation Would Encourage More Generic and Biosimilar Competition in the Prescription Drug Market to Help Lower Costs for Patients (Washington, D.C.) — The Pharmaceutical
PCMA Releases Commitment to Unlocking an Affordable Health Care Future
PCMA Policy Platform Prioritizes Patients with Solutions to Promote Competition, Lower Drug Costs, Support Better Health Outcomes & Maximize the Value of Pharmacy Benefits (Washington,
PerformRx President Jim Gartner Joins PCMA Board of Directors
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) announced today that PerformRx President Jim Gartner, MBA, R.Ph., is joining the trade association’s board of
PCMA Releases New Policy Recommendations to Remove Barriers to Biosimilars, Lower Drug Costs
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of
PCMA Launches Educational Campaign in Honor of World Diabetes Day
(Washington, D.C.) — In honor of World Diabetes Day, the Pharmaceutical Care Management Association (PCMA) has launched a new phase of the OnYourRxSide campaign that
Express Scripts President Amy Bricker Becomes PCMA Board Chair
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) is pleased to announce that Amy Bricker, RPh, president of Express Scripts, has assumed the role
Don’t Be Fooled: Big Pharma Keeps the Vast Majority of the Rx Dollar
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug
Disclosure Requirements Could Impact Manufacturer Rebates
New report finds a potential result of disclosure requirements could increase federal government costs by $134 billion over 10 years Congress continues to consider proposals
New PCMA Rx Research Corner Blog Post: Dr. Lawton Robert Burns Sheds Light on the Role of PBMs
“PBMs promote competition in healthcare and help to reduce prices,” said Lawton Robert Burns Hot Off the Presses: University of Pennsylvania Wharton School professor Lawton
New Legislation Aims to Increase Competition in U.S. Biosimilar Market
Pharmacy benefit companies are strong proponents of a highly functioning biosimilar market. Bringing more biosimilars to market, over time, will allow PBMs to more effectively
Eliminating Spread Pricing Would Lead to Higher Costs and Fewer Choices for America’s Employers
What is spread pricing? Spread pricing is a contract option for employers and plan sponsors who want their pharmacy benefit company to carry the risk that pharmacies
Misguided Legislation Puts Innovation and Savings Delivered by Pharmacy Benefit Industry at Risk
In case you missed it, PCMA President and CEO JC Scott joined Prime Therapeutics’ webinar Beyond the Script: PBM Hot Topics in D.C. to discuss how
Big Pharma Returns with Self-Serving Policies Already Rejected by Congress
While Big Pharma pushes misguided policies targeting pharmacy benefits as part of a blame game designed to keep prescription drug prices high, former Members of
A World Without Pharmacy Benefit Companies? Ask the Department of Labor
The vast majority of employers and public health programs voluntarily work with pharmacy benefit companies to manage pharmacy benefits. So, what happens when a health
Robust U.S. Biosimilar Market Will Encourage Competition and Lower Prescription Drug Costs for Patients
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play
94 Percent Of The Drug Dollar Is Retained By Drug Manufacturers, Drug Wholesalers, And Pharmacies
A simple fact is often lost in the din of the current drug pricing debate going on in Washington D.C. and around the country: Drug